Research Article

The Impact of the Coexpression of MET and ESR Genes on Prognosticators and Clinical Outcomes of Breast Cancer: An Analysis for the METABRIC Dataset

Table 2

Association of the MET/ESR gene expression status with clinicopathologic characteristics in patients with breast cancer.

ParameterExpression status valueExpression status value
(n = 299) (n = 403) (n = 591) (n = 452)

Stage0.7460.001
 Early191 (40.6)280 (59.4)411 (58.1)297 (41.9)
 Advanced14 (37.8)23 (62.2)27 (37.5)45 (62.5)
Grade<0.001<0.001
 I/II92 (27.2)246 (72.8)311 (63.7)177 (36.3)
 III198 (58.1)143 (41.9)255 (49.5)260 (50.5)
ER<0.001<0.001
 Positive150 (28.0)385 (72.0)517 (63.7)295 (36.3)
 Negative146 (92.4)12 (7.6)65 (30.1)151 (69.9)
PR<0.001<0.001
 Positive86 (22.8)291 (77.2)372 (65.0)200 (35.0)
 Negative213 (65.5)112 (34.5)219 (46.5)252 (53.5)
HER2<0.0010.064
 Positive77 (76.2)24 (23.8)58 (48.7)61 (51.3)
 Negative222 (36.9)379 (63.1)533 (57.7)391 (42.3)
Molecular subtype<0.001<0.001
 Luminal70 (17.8)323 (82.2)458 (70.4)193 (29.6)
 Non-luminal229 (74.8)77 (25.2)132 (33.9)257 (66.1)

Data are presented as n(%). Chi-square test. Indicates statistical significance at . ER: estrogen receptor; HER2: human epidermal growth factor receptor 2; PR: progesterone receptor.